A Phase 3 clinical trial studying cagrilintide has changed status to active, not recruiting, as of August 6, 2026. The trial is titled "Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide." It is registered under identifier NCT07220642 on ClinicalTrials.gov.
Cagrilintide remains an unapproved compound used only in research settings. This update reflects a change in recruitment status, not the release of any trial results. No efficacy or safety outcomes have been reported in connection with this update.
The trial is designated Phase 3, indicating it is in a later stage of clinical investigation. Active, not recruiting means the study is ongoing but is no longer enrolling new participants at this time. Further updates may follow as the trial progresses toward completion or reports findings.
Readers interested in this compound can consult the compound overview for additional background and context.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07220642"]